细胞自噬与AD
1962年Ashford 和Porter 发现细胞内有“自己吃自己”的现象,之后提出的自噬(Autophagy),自噬的概念是指细胞受损后,损伤或衰老的细胞器或蛋白质被运送到溶酶体内,与溶酶体融合形成自噬溶酶体降解其所包裹的内容物。
自噬可以降解损伤衰老及功能异常的细胞器和相关蛋白,而是AD特征的病理改变细胞外大量老年斑的形成及NFTs,这就表示自噬在AD 的发病中占有一定的调控作用。现进一步研究发现:自噬溶酶体系统可通过CCN2 调控γ-分泌酶的活性,在AD 患者脑中,Aβ的过度生成可能由神经纤维网广泛自噬的增加导致,而且细胞实验也已发现自噬可以抑制Aβ诱导的神经毒性作用而发挥神经保护作用。但是具体的分子机制及相关病理过程仍需探索。
以上结果足以证明自噬与神经退行性病变(如帕金森病、AD)等密切相关。虽然目前还不能确定AD是否能通过靶向治疗来完成治愈,但是关于细胞自噬的治疗是相当有前景的。
综上所述,AD的发病机制目前主要有Aβ毒性学说、Tau蛋白学说、血管因素学说及基因学说等,而其发病机制可能涉及多种学说,由此可见AD的发病机制异常复杂,可能涉及多条分子信号通路,包括Aβ、Tau蛋白及突触异常等。各机制之间相互联系,共同促使神经元变性。今后的研究需全面揭示多种发病机制之间的联系,以同时阻断多条信号通路等。目前,AD防治研究依然任重而道远。
参考文献
[1]吴江.神经病学[M].3版.北京:人民卫生出版社,2015:364.
[2]Lendon CL,Ashall F,Goate AM.Exploring the etiology of Alzheimer disease using molecular genetics[J].JAMA,1997,277(10):825-831.
[3]Carrasquillo MM,Belbin O,Hunter TA,et al.Replication of CLU,CR1,and PICALM associations with alzheimer disease[J].Arch Neurol,2010,67(8):961-964.
[4]Feulner TM,Laws SM,Friedrich P,et al.Examination of the current top candidate genes for AD in a genome-wide association study[J].Molecular Psychiatry,2010,15(7):756-766.
[5]Chesler EJ,Lu L,Shou S,et al.Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function[J].Nat Genet,2005,37(3):233-242.
[6]Chou PS,Wu MN,Chou MC,et al.Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer's insertion disease[J].Geriatr Gerontol Int,2016,doi:10.1111/ggi.12929.[Epub ahead of print].
[7]Shibata N,Kawarai T,Lee JH,et al.Association studies of cholesterol metabolism genes(CH25H,ABCA1 and CH24H)in Alzheimer ' s disease[J].Neurosci Lett,2006,391(3):142-146.
[8]Lamsa R,Helisalmi S,Herukka SK,et al.Study on the association SOAT1 between polymorphisms,Alzheimer's disease risk and the level of CSF biomarkers[J].Dement Geriatr Cogn Disord,2007,24(2):146-150.
[9]Reddy PH,Tonk S,Kumar SA,et al.A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer ' s disease[J].Biochem Biophys Res Commun,2017,483(4):1156-1165.
[10]李国辉.载脂蛋白E4基因型预测老年缺血性脑血管病复发的意义[J].中国老年学杂志,2015,35(6):1594-1596.
[11]王美琴,杨铠冰,张敏.阿尔茨海默病的基因组学研究进展[J].中国康复理论与实践,2015,21(12):1365-1369.
[12]陈茜.SILAC 定量蛋白质组学分析及线粒体相关的机制研究[D].石家庄:河北医科大学,2015.
[13]Arighi CN,Hartnell LM,Aguilar RC,et al.Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor[J].CellBiol,2004,165(1):123-133.
[14]Zimprich A,Benet-Pages A,Struhal W,et al.A mutation in VPS35,encoding a subunit of the retromer complex,causes late-onset Parkinson disease[J].Am J Hum Genet,2011,89(1):168-175.
[15]MacLeod DA,Rhinn H,Kuwahara T,et al.RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk[J].Neuron,2013,77(3):425-439.
[16]Kaether C,Haass C,Steiner H.Assembly,trafficking and function of γsecretase[J].Neurodege Dis,2006,3:275-283.
[17]Kim SJ,Ahn JW,Kim H,et al.Two β-strands of RAGE participate in the recognition and transport of amyloid-β peptide across the blood brain barrier[J].Biochem Biophys Res Commun,2013,439(2):252-257.
[18]Xiong H,Callaghan D,Jones A,et al.ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the bloodbrain barrier for Abeta(1-40)peptides[J].J Neurosci,2009,29(17):5463-5475.
[19]Li Y,Dunn L,Greggio E,et al.The R1441C mutation alters the folding properties of the ROC domain of LRRK2[J].Biochim Biophys Acta,2009,1792(12):1194-1197.
[20]Tijero B,Gómez Esteban JC,Somme J,et al.Autonomic dysfunction in parkinsonian LRRK2 mutation carriers[J].Parkinsonism Relat Disord,2013,19(10):906-909.
[21]Su YC,Qi X.Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation[J].Hum Mol Genet,2013,22(22):4545-4561.(https://www.daowen.com)
[22]Biskup S,Moore DJ,Celsi F,et al.Localization of LRRK2 to membranous and vesicular structures in mammalian brain[J].Ann Neurol,2006,60(5):557-569.
[23]Hatano T,Kubo S,Imai S,et al.Leucine-rich repeat kinase 2 associates with lipid rafts[J].Hum Mol Genet,2007,16(6):678-690.
[24]Alegre-Abarrategui J,Wade-Martins R.Parkinson disease,LRRK2 and the endocytic-autophagic pathway[J].Autophagy,2009,5(8):1208-1210.
[25]Gandhi PN,Wang X,Zhu X,et al.The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules[J].J Neurosci Res,2008,86(8):1711-1720.
[26]Gloeckner CJ,Kinkl N,Schumacher A,et al.The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity[J].Hum Mol Genet,2006,15(2):223-232.
[27]Gillardon F.Leucine-rich repeat kinase 2 phosphorylates brain tubulinbeta isoforms and modulates microtubule stabilitya point of convergence in parkinsonian neurodegeneration?[J].J Neurochem,2009,110(5):1514-1522.
[28]Kiely AP,Asi YT,Kara E,et al.Alpha-Synucleinopathy associated with G51D SNCA mutation:a link between Parkinson's disease and multiple system atrophy?[J].Acta Neuropathol,2013,125(5):753-769.
[29]Korff A,Liu C,Ginghina C,et al.α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment[J].J Alzheimers Dis,2013,36(4):679-688.
[30]Resende R,Marques SC,Ferreiro E,et al.Effect of alpha-synuclein on amyloid beta-induced toxicity:relevance to lewy body variant of Alzheimer disease[J].Neurochem Res,2013,38(4):797-806.
[31]Zhang NY,Tang Z,Liu CW.Alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation:understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis[J].J Biol Chem,2008,283(29):20288-20298.
[32]Winslow AR,Rubinsztein DC.The Parkinson disease protein α-synuclein inhibits autophagy[J].Autophagy,2011,7(4):429-431.
[33]Hellstrom-Lindahl E,Viitaen M,Marutle A.Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease[J].Neurochem Inter,2009,55(4):243-252.
[34]Alafuzoff I,Arzberger T,Al-Sarraj S,et al.Staging of neurofibrillary pathology in Alzheimer's disease:a study of the Brain Net Europe Consortium[J].Brain Pathol,2008,18(4):484-496.
[35]Yang Y,Yang XF,Wang YP,et al.Inhibition of protein phosphatases induces transport deficits and axonopathy[J].J Neurochem,2007,102(3):878-886.
[36]Glenner GG,Wong CW.Alzheimer's disease and Down's syndrome:sharing of a unique cerebrovascular amyloid firil protein[J].Biochem Biophys Res Commun,1984,122(3):1131-1135.
[37]Seshadri S,Beiser A,Selhub J,et al.Plasma homocysteine as a risk factor for dementia and Alzheimer's disease[J].N Engl J Med,2002,346(7):476-483.
[38]Yang B,Sun X,Lashuel H,et al.Oxidative stress in Alzheimer's disease[J].Neurosci Bull,2012,28(3):233-239.
[39]Santo-Domingo J,Wiederkehr A,De Marchi U.Modulation of the matrix redox signaling by mitochondrial[J].World J Biol Chem,2015,6(4):310-323.
[40]李晓晴,王力,冯立群,等.阿尔茨海默病的发病机制和细胞周期假说[J].中华神经医学杂志,2011,10(7):752-754.
[41]Macmillan KS,Naidoo J,Liang J,et al.Development of proneurogenic,neuroprotective small molecules[J].J Am Chem Soc,2011,133(5):1428-1437.
[42]梁维维,梁庆成,吴云.5-羟色胺与阿尔茨海默病的关系研究进展[J].中国老年学杂志,2013,33(3):735-737.
[43]Fernandez-Vizarra P,Lopez-Franco O,Mallavia B,et al.Immunoglobulin GFc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment inmice[J].Brain,2012,135(9):2826-2837.
[44]杨连勇.阿尔茨海默病发病机制进展[J].中国民康医学,2014,26(23):79-90.
[45]Shepardson NE,Shankar GM,Selkoe DJ.Cholesterol level andstatinuse in Alzheimer disease:Review of epidemiological and preclinical studie[J].Arch Neurol,2011,68(10):1239-1244.
(叶 民)